Allovir, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.allovir.com

Market Cap $60.32M
PE -1
Debt $NaN
Cash $116.86M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$100.20M
EBIT	-$105.61M
ROE	-83%
ROA	-86%
Equity	$121.12M
Growth Stability	1
PE	-0.6
PB	0.5
Price/Cash	1.94
Equity CAGR	-22%
Earnings Growth YoY	-91%
Earnings Growth QoQ	-32%

Equity CAGR 5Y	-23%
Equity CAGR 3Y	-20%
Market Cap	$60.32M
Assets	$122.53M
Cash	$116.86M
Shares Outstanding	115.07M
Working Capital	121.12M
Current Ratio	86.78
Shares Growth 3y	30%
Equity Growth QoQ	1%
Equity Growth YoY	-38%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

SEC Filings

Direct access to Allovir, Inc. (ALVR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Allovir, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Allovir, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Allovir, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Allovir, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-14K%	-	-	-	-	-
ROA	-	-19%	-59%	-61%	-100%	-86%
ROE	-	-20%	-76%	-75%	-131%	-83%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-
Earnings YoY growth	-	193%	146%	-2%	13%	-
Equity YoY growth	-	-786%	-36%	-0%	-35%	-23%
FCF YoY growth	-	198%	74%	-	-	-